Recordati Industria Chimica e Farmaceutica S.p.A. (0KBS.IL)

49.83 +0.68 (+1.38%) At close: 04:36PM BST

Recordati Industria Chimica e Farmaceutica S.p.A.

Via Matteo Civitali,1
Milan, MI 20148
Italy
39 02 487871
https://www.recordati.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 4,300

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Robert Koremans M.D.	CEO & Director	1.81M	N/A	1962
Mr. Luigi Felice La Corte	Group CFO & Exec. Director	948k	N/A	1969
Ms. Cathrin Petty	Exec. Director	N/A	N/A	1973
Mr. Giampiero Mazza	Exec. Director	N/A	N/A	1969
Mr. Giorgio De Palma	Exec. Director	N/A	N/A	1974
Ms. Federica De Medici	Director of Investor Relations & Corp. Communications	N/A	N/A	N/A
Ms. Bibianne Bon	Group Chief Legal Officer	N/A	N/A	N/A
Mr. Gabriele Finzi	Exec. VP of Corp. Devel., Licensing & Innovation	N/A	N/A	N/A
Mr. Giuseppe Gualazzini	Sr. VP of Group HR	N/A	N/A	1959
Mr. Roberto Teruzzi	Exec. VP of Group Industrial Operations	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

Corporate governance

Recordati Industria Chimica e Farmaceutica S.p.A.’s ISS governance QualityScore as of 1 October 2023 is 3. The pillar scores are Audit: 3; Board: 7; Shareholder rights: 3; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.